Equity
€409,268 ▲ 16.6%
VA PHARMA has made a profit without a break since 2022.
VA PHARMA
Lifetime
13 annual accounts with figures on one time axispeak €194,976 (2024)
€161,071▼ 17.4%
lowest -€38,251 (2019)
€58,359▼ 25.6%
peak €409,268 (2025)
€409,268▲ 16.6%
€488,974▼ 11.2%
peak 0.6 FTE (2014)
0.6 FTEunchanged
Board3 names since 2012
2 directors and 1 other
Documentsfilings and deeds
27-08-202627 days late
2025abbreviated format
Gross margin from €194,976 to €161,071Result from €78,462 to €58,359Equity from €350,908 to €409,268Cash from €217,542 to €298,103
Key points
from the 2025 annual accountsChecked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 34,721 companies had the same profile as VA PHARMA has now. Each dot stands for 87 companies, two years later.
95.3%
were still trading
4.0%
stopped another way
0.7%
went bankrupt
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 34,721 companies, not a prediction for VA PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Managing director
Director, since 18-12-2012
- 50 sharesdeed of 01-02-2024
- 50 sharesdeed of 01-02-2024
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0508521312
Amendment of the articles · Legal-form change · Resignations & appointments
Resignation: (manager) · Appointment: (director and managing director) · Permanent representatives: and · General meeting of 24-01-2024 · Gazette deed
Incorporation
published on 20-12-2012 · Gazette deed
First establishment
Rue de Robiano 66, Binche
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| VA PHARMA Binche | €0.9m | €161,071 | 45.6% | 0.6 |
| Apotheek Ghesquiere Zonnebeke | €0.9m | €187,592 | 87.4% | 0.8 |
| Apotheek Hever Boortmeerbeek | €0.9m | €200,322 | 44.5% | 0.7 |
| Apotheek Sigrid Saelens Poperinge | €1.1m | €138,640 | 77.2% | 0.7 |
| SOBEGAPHARMA Mons | €1.0m | €183,099 | 18.1% | 0.8 |
| PHARMACIE DU BEAU SITE Charleroi | €0.9m | €148,476 | 6.7% | 1.1 |
| PHARMACIE ARS SYLVIE Soignies | €0.6m | €191,269 | 43.2% | 0.7 |
These companies have the same main activity as VA PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €647,000 and €1.1m, founded between 2008 and 2015.
Official details
Source: KBO- Status
- Active since 18-12-2012Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Establishment unit
- 2.215.649.7497130 Binche, since 18-12-2012
- Financial year end
- 31 December
- Peppol
- Reachable since 27-11-2025
Insights on VA PHARMA
VA PHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €121,833 in 2013 to €161,071 in 2025.
In February 2024, the Official Gazette published the appointment of as managing director.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about VA PHARMA
- What is the company number of VA PHARMA?
- The company number of VA PHARMA is 0508.521.312. The VAT number is the same number with BE in front: BE 0508.521.312.
- Where is VA PHARMA based?
- The registered office is at Rue de Cent Pieds 86, 7133 Binche.Company details
- What does VA PHARMA do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of VA PHARMA?
- VA PHARMA is a private limited company (BV).
- When was VA PHARMA founded?
- VA PHARMA was founded on 18-12-2012.
- Is VA PHARMA still active?
- Yes, VA PHARMA is an active enterprise in the KBO register.
- How many employees does VA PHARMA have?
- VA PHARMA had an average of 0.6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of VA PHARMA?
- The turnover in financial year 2025 is ≈ €750,000. This figure is estimated from the gross margin of €161,071 and 52 comparable companies (NACE 477). It probably lies between €510,000 and €1.4m.
- Is VA PHARMA profitable?
- In financial year 2025, VA PHARMA made a profit of €58,359.
- Where can I find the annual accounts of VA PHARMA?
- VA PHARMA filed 13 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of VA PHARMA due?
- VA PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.